New Diabetes Technology: A Test

May 7, 2018

The new diabetes tech in question is the expanding pool of continuous glucose monitoring systems. So, what's your CGM IQ?

The new diabetes tech you'll be tested on here comes from the expanding pool of continuous glucose monitoring systems, eg, the Eversense CGM and the FreeStyleÂ® Libre Flash. How much do you know about the features and benefits of these and their competitors? Find out with our short, 5-question quiz.

New Diabetes Technology: A Test

Question 1: What is the first FDA-approved integrated CGM monitor?

Answer: D. The Dexcom G6 integrated CGM was FDA approved on March 27, 2018 and is the first CGM that can form an integrated system with compatible devices. It is approved for children aged 2 years or older and sends real-time glucose readings every 5 minutes to a mobile app and sends an alarm for hyper- and hypoglycemia.

For more information, go to: FDA authorizes first fully interoperable continuous glucose monitoring system, streamlines review pathway for similar devices.

Question 2: What is true about the Eversense implantable CGM?

Answer: A. The Eversense implantable CGM is about the size and thickness of a Tylenol tablet. While it is not FDA approved, Senseonics plans for FDA safety evaluation in 2018.

For more information on the Eversense CGM, go to: eversensediabetes.com.

Question 3: What are the advantages of the MiniMed 630G and 670G?

Answer: D. The MiniMed 630G and 670G are both hybrid closed loop systems with a glucose meter and a CGM wirelessly connected to an insulin pump. The 630G is indicated for people aged 16 and older and the 670G is indicated for people aged 14 and over.

For more information on the MiniMed 630G, go to: MiniMed 630G System with SmartGuard - P150001/S021

For more information on the MiniMed 670G, go to: MiniMed 670G System - P160017/S017

Question 4: What is not true about the FreeStyle Libre Flash Glucose Monitoring system?

Answer: C. The FreeStyle® Libre Flash Glucose Monitoring system is the only FDA-approved CGM that does not require fingerstick calibration and was FDA-approved in September 2017.

For more information, go to: No More Routine Finger Sticks For Americans With Diabetes: Abbott′s Freestyle® Libre Approved in the U.S.

Question 5: Which of the above is true?

Answer: C. The FDA has approved two artificial pancreas device systems to date: Medtronic’s MiniMed 670G and the MiniMed 630G.

For more information, go to: The Artificial Pancreas Device System